Innate Pharma (IPHA) said Wednesday it will seek approval from shareholders to change its governance from the current executive board/supervisory board structure to one with a CEO and board of directors.
The change, which aims to simplify and align the company's governance with international standards, will be proposed at the annual general meeting on May 22, Innate Pharma said.
If shareholders approve the change, current supervisory board chairwoman Irina Staatz-Granzer would be appointed chairwoman of the board, and current executive board chairman Jonathan Dickinson would be appointed CEO, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。